Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise against tough lung cancer

NCT ID NCT04995523

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 27 times

Summary

This study tests an experimental drug called rilvegostomig (AZD2936) in people with advanced or metastatic non-small cell lung cancer (NSCLC) that cannot be removed by surgery. The drug is a bispecific antibody that targets two immune checkpoints (TIGIT and PD-1) to help the immune system fight cancer. The trial involves about 212 adults and aims to check safety, side effects, and how well the drug shrinks tumors. Since participants may need ongoing treatment, this is classified as disease control, not a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Chicago, Illinois, 60637, United States

  • Research Site

    Rochester, Minnesota, 55905, United States

  • Research Site

    Fairfax, Virginia, 22031, United States

  • Research Site

    Melbourne, 3000, Australia

  • Research Site

    Anderlecht, 1070, Belgium

  • Research Site

    Leuven, 3000, Belgium

  • Research Site

    Florianópolis, 88034-000, Brazil

  • Research Site

    Natal, 59075-740, Brazil

  • Research Site

    Porto Alegre, 90035903, Brazil

  • Research Site

    Rio de Janeiro, 20231-050, Brazil

  • Research Site

    São Paulo, 01246-000, Brazil

  • Research Site

    Chengdu, 610041, China

  • Research Site

    Chongqing, 400030, China

  • Research Site

    Copenhagen, 2100, Denmark

  • Research Site

    Dijon, 21079, France

  • Research Site

    Toulouse, 31059, France

  • Research Site

    Tbilisi, 0112, Georgia

  • Research Site

    Kashiwa, 227-8577, Japan

  • Research Site

    Niigata, 951-8566, Japan

  • Research Site

    Sendai, 981-0914, Japan

  • Research Site

    Tokyo, 104-0045, Japan

  • Research Site

    Kuala Lumpur, 59100, Malaysia

  • Research Site

    Kuching, 93586, Malaysia

  • Research Site

    Chisinau, MD-2025, Moldova

  • Research Site

    Groningen, 9713 GZ, Netherlands

  • Research Site

    Leiden, 2333 ZA, Netherlands

  • Research Site

    Utrecht, 3584 CX, Netherlands

  • Research Site

    Seoul, 03082, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Barcelona, 08035, Spain

  • Research Site

    Madrid, 28027, Spain

  • Research Site

    Madrid, 28041, Spain

  • Research Site

    Taichung, 40201, Taiwan

  • Research Site

    Taichung, Taiwan

  • Research Site

    Tainan, 70403, Taiwan

  • Research Site

    Taipei, 110, Taiwan

  • Research Site

    Bangkok, 10700, Thailand

  • Research Site

    Chanthaburi, 22000, Thailand

  • Research Site

    Muang, 50200, Thailand

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CARCINOMA NON-SMALL-CELL LUNG CARCINOMA